Scientists at the Vanderbilt-Ingram Cancer Center have developed a new mouse model for pancreatic cancer that exhibits similar properties to a human tumor. Hal Moses and his team developed this improved model by combining a previous model called Kras with type II TGF receptor. Cell biology suggests loss of TGF signals causes a molecular imbalance on the cell growth leading to unrestrained cell proliferation and tumor formation. Applying this theory, genetically engineered mice with pancreatic cancer have been created for providing researchers opportunities to investigate on various treatments and screening methods to fight one of the most deadly cancers.
In another development, researchers at the University of Texas M D Anderson Cancer Center have discovered a new vascular targeting agent called Trojan Horse that shows hopes for treating bone tumors. A pre-clinical study conducted on mice revealed that Trojan Horse successfully prevented the development of bone tumors in 50 per cent mice. Although the experiment is still underway but scientists are hopeful that the success on mice could be a promising indication to tackling cancers in bones such as breast, multiple myeloma, lung and renal cell.
Peregrine Pharmaceuticals Inc, a clinical stage biopharmaceutical company is initiating its phase lb clinical trial to evaluate its anti-phospholipid immunotherapy agent, bavituximab given in combination with common cancer chemotherapy agents. The preclinical trial had suggested that agent bavituximab was very effective when combined with normal chemotherapy. The human trial is expected to enroll up to 12 patients who will be observed for 8-week duration at three clinical sites in India. The trial will check bavituximab for safety and tolerability when administered with standard chemotherapy regimens.
Powered by Qumana